Oncology (Williston Park). 2019 Aug 23;33(8):683730.
Brain metastasis is a poor prognostic factor in breast cancer progression, and traditional treatment options have shown minimal response with overall low median survival rates. The incidence of brain metastasis has been increasing despite and, in part, due to advancements in treatment as a result of prolongation of survival. Targeted therapy such anti-HER2 agents have a lower efficacy in this setting compared to metastases elsewhere; however, novel therapies are emerging in this regard. In this comprehensive review, we discuss risk per subtype, special considerations for therapy selection, current focal and systemic treatments, and recent advancements and potential future targets for success. We present our treatment paradigm and multidisciplinary approach to brain metastases arising from breast cancer based on the available evidence, incorporating molecular characteristics.
脑转移是乳腺癌进展的预后不良因素，传统的治疗选择反应甚微，总中位生存率较低。尽管部分原因是由于治疗进展延长了生存时间，导致脑转移的发生率一直在增加。针对 HER2 的靶向治疗在这种情况下的疗效较低与其他部位的转移相比;然而，在这方面新的治疗方法正在出现。在这篇全面的综述中，我们讨论了每种亚型的风险，治疗选择的特殊考虑因素，目前的局部和全身治疗，以及最近的进展和成功的潜在未来靶点。根据现有证据，结合分子特征，我们提出了我们的治疗模式和多学科方法，以治疗乳腺癌引起的脑转移。
